



STABLEBODY TECHNOLOGIES, LLC



StableBody, LLC

Company Overview: Stablebody Technologies has optimized a method that improves dramatically recombinant antibody stability as a formulation tool for therapeutic and diagnostic markets.

Problem: Many antibodies that show promising results in basic research laboratory tests for diagnostic or therapeutic applications, fail to emerge as diagnostic or therapeutic products. The successful transition of antibodies from a small scale laboratory environment to a manufacturing scale setting depends on the condition and the robustness of the particular antibody, its suitability to large scale production and by storage, handling and temperature requirements.

Solution: Optimizing antibody structure and design accelerates the development process, enhances the product efficacy, facilitates manufacturing, and improves the product's use and application capabilities.

Business Model: Stablebody Technologies will leverage its stabilization services to develop high value, proprietary targets in the therapeutic and diagnostic markets. The company was founded by a leading scientist in the Biosciences Division of Argonne National Laboratories and has obtained the license for use of this state of the art technology.

Marketing Opportunity: Recombinant antibodies have significant advantages in that no animals are needed in the manufacturing procedure of the recombinant antibodies, the manufacturing time is relatively short and the quality of the final product is higher than the non-recombinant method. This achievement has allowed for the custom design of monoclonal antibodies to meet development and production needs in the therapeutic and diagnostic sectors. There are currently over 400 other antibodies in various development stages. The current global therapeutic market is over \$25 billion and will approach \$45 billion by 2012. The average annual growth rate for therapeutic area is 11.5 percent. Current diagnostic antibody sales exceed \$8 billion annually.

Competitive Advantage: This novel method of antibody stabilization differs significantly from other recently developed methods. Stablebody Technologies method is quicker (months vs. years), easier (directed vs. random incremental change approach), and therefore, less expensive. Most important, the method accelerates the development process, enhances the product efficacy, facilitates manufacturing and improves the product's use and application abilities.

Management Team: The Stablebody Technologies management team has extensive backgrounds in the bioscience fields with over 100 years of cumulative experience in research, development, commercialization and entrepreneurship. Dr. Fred Stevens, CSO; Dr. Joseph Firca CEO; H. Rossiter Horn, COO; and Dr. Edward Corrigan, CFO.

Funding Request: Stablebody Technologies seeks \$6 million in private equity financing to cover initial capitalization, startup operations, working capital and contingency purposes.



H. ROSSITER HORN

*Investors: Founders
Year Founded: 2009
Employees: 5*

*Stablebody, LLC
4675 Signature Drive
Middleton, WI 53562
608-698-8445
hrhorn@stablebodytech.com
www.stablebodytech.com*

*In Attendance:
H. Rossiter Horn, R.Ph.*

*Revenue Forecast:
2010: \$.75M
2011: \$ 2.3M*